Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Blood (2021) 138 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2021-150369

Published: 2021

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Blood (2021) 138 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2021-146940

Published: 2021

Journal Articles

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Blood (2021) 138 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2021-144421

Published: 2021

Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134935

Published: 2020

Journal Articles

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin Kingsley, Jerry Ping, Darrin M. Beaupre, Jutta K. Neuenburg, Jia Ruan

Blood (2019) 134 (13): 1024–1036.

https://doi.org/10.1182/blood.2018891598

Published: 2019

Includes: Supplemental data

Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD

Blood (2016) 128 (22): 473.

https://doi.org/10.1182/blood.V128.22.473.473

Published: 2016

Journal Articles

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Auayporn P. Nademanee, MD, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Dave Yamauchi, MD, Maria Delioukina, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Eileen Smith, MD, Anthony Stein, MD, Neil Kogut, MD, Margaret O'Donnell, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 3357.

https://doi.org/10.1182/blood.V114.22.3357.3357

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Robert Chen, MD, Joycelynne Palmer, PHD, Leslie Popplewell, MD, Jessica Shen, MS, Eileen Smith, MD, Maria Delioukina, MD, Neil Kogut, MD, Joseph Rosenthal, MD, Stephen J Forman, MD, Auayporn P. Nademanee, MD

Blood (2009) 114 (22): 1192.

https://doi.org/10.1182/blood.V114.22.1192.1192

Published: 2009

Journal Articles

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Mark Kirschbaum, MD, Maria Delioukina, Leslie Popplewell, MD, David S. Snyder, MD, Pablo Parker, Robert Chen, MD, Jasmine Zain, MD, Deron Matsuoka, Nony Obadike, Paul Frankel, Auayporn P. Nademanee, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 1682.

https://doi.org/10.1182/blood.V114.22.1682.1682

Published: 2009

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

Mark Kirschbaum, MD, Leslie Popplewell, Auayporn P. Nademanee, Vinod Pullarkat, Maria Delioukina, Jasmine M. Zain, Deron Matsuoka, Bernadette Pulone, Paul Frankel, Igor Espinoza-Delgado, MD, Stephen J. Forman, David Gandara, Edward Newman

Blood (2008) 112 (11): 1564.

https://doi.org/10.1182/blood.V112.11.1564.1564

Published: 2008

Journal Articles

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, Jeffrey Y. Wong, George Somlo, David Snyder, Margaret O’Donnell, Anthony Stein, Ayurporn Nademanee, Maria Delioukina, Leslie Popplewell, Pablo Parker, Ricardo Spielberger, Firoozeh Sahebi, Chatchada Karanes, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Stephen Forman

Blood (2008) 112 (11): 3271.

https://doi.org/10.1182/blood.V112.11.3271.3271

Published: 2008

Journal Articles

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, MD, Jeffrey Wong, MD, Anthony Stein, MD, Ellen Bolotin, MD, PhD, Chatchada Karanes, MD, Leslie Popplwell, MD, Auayporn Nademanee, MD, Firoozeh Sahebi, MD, Margaret O’Donnell, MD, Maria Delioukina, MD, George Somlo, MD, Anna Pawlowska, MD, Debbie Hitt, RN, Marianna Shakhnovits, MD, Stephen Forman, MD

Blood (2007) 110 (11): 3021.

https://doi.org/10.1182/blood.V110.11.3021.3021

Published: 2007

NARROW

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

Adding Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy to Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) in Patients (pts) with Advanced Hematological Malignancies.

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only